(Theme 3) SARS-CoV-2 Enzymology
- Funded by UK Research and Innovation (UKRI)
- Total publications:0 publications
Grant number: C19-IUC-361
Grant search
Key facts
Disease
COVID-19Funder
UK Research and Innovation (UKRI)Principal Investigator
John DiffleyResearch Location
United KingdomLead Research Institution
Francis Crick InstituteResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
SARS-CoV-2 is a (+) strand RNA virus encoding a polyprotein which is cleaved into 16 separate non-structural proteins (Nsp). Nine of the 16 proteins are enzymes and represent obvious candidates for small molecule inhibitors. These enzymes are highly conserved and essential for viral growth. Our aim is to validate these biological targets for therapeutic use using a small molecule validation set of FDA approved small molecules. We will explore both repurposing of existing drugs and discovery of new leads targeting these enzymes to develop new therapies.